sanofi

  1. Sanofi Hiring Internal Only

    Reading different posts & all true. Sanofi does dog & pony show when it comes to hiring. 95% of jobs go internal. I know because I work here. Recent national meeting more transfer deals being done & approved at breaks it was insane. Everyone wanting on Dupixent train. Sorry folks if you are...
  2. Hiring at Sanofi

    applied for a business role and went on several interviews between December and January. No news weeks after my final interview and workday status remains under consideration. Does anyone know if there’s a hiring freeze at sanofi or if I’m effectively rejected?
  3. Novo Nordisk reports first quarter results

    Novo Nordisk says pricing pressure within diabetes to continue, especially in the US. First quarter 2019 results: Sales from North America Operations declined 4% on constant exchange rates.
  4. Amarin will bounce back

    I expect that Amarin will bounce back from the recent sell-off. Most of the doctors who participated in the AHA event has said that they will prescribe Vascepa and next year the biggies like Pfizer might considering acquiring Amarin...
  5. Celgene Q2 earnings - no further price hike in products this year

    Celgene's second quarter results beat estimates and the company lifted 2018 outlook. Celgene will not be increasing the price of its products this year. https://news.alphastreet.com/celgene-q2-2018-earnings/
  6. Sanofi nears deal to sell its generic business unit Zentiva

    Sanofi plans to offload its European generics business Zentiva that it acquired in 2009. Several bidders had earlier dropped out of an auction, but latest news suggests that the company is nearing an agreement and may soon finalize the sale. According to Reuters, private equity firm Advent...
  7. Novartis-AveXis : A ‘gene’-ius deal?

    Novartis is wagering high on gene therapy with its proposed acquisit ion of AveXis Inc. valued at $8.7 billion. The high-premium deal is expected to be completed in mid-2018. Source https://news.alphastreet.com/novartis-avexis-a-gene-ius-deal/ "The pharmaceutical sector is witnessing many...
  8. Pfizer’s dilemma: To sell or not to sell

    Pfizer (PFE) has been contemplating on selling its consumer healthcare division for some time, and it had found two bidders - British pharmaceutical giants GlaxoSmithKline and Reckitt Benckiser. However, with Reckitt announcing its decision to back out of the race yesterday to pursue its $16.6...
  9. New flu vaccine brings Novavax back to life

    https://news.alphastreet.com/new-flu-vaccine-brings-novavax-back-to-life/ Novavax claims that NanoFlu was almost 47-64% more effective against different strains of the nastiest H3N2, when compared to the standard flu vaccines.
  10. Dupixent Regeneron Sales Reps

    Does anyone know how Regeneron's sales team compares to Sanofi's and about how many people they have in the field? Seems like a pretty equal split?
  11. Kevzara performance

    Wow $9M sales worldwide in Q4, that's what I call a gusher. :cool:
  12. Juno buyout buzz becomes true

    It's an M&A Monday for the pharma companies. Two major pharma acquisitions announced today. 1) Celgene acquires Juno for $9 billion http://alph.st/pd7bf702 2) Sanofi acquires Bioverative for $11.6 billion Last week, there was a rumor that Celgene's acquisition of Juno and also news about...
  13. Celgene strengthens cancer portfolio

    Celgene strengthens its cancer portfolio by acquiring Impact Biomedicines. After stopping the Crohn's disease treatment trials and cutting down the 2020 outlook recently, this deal is a positive news for Celgene. But Sanofi had sold the rights of fedrantinib to Impact in 2016 when the drug was...
  14. Diabetes - Lilly's competition with Sanofi

    Lilly's Humalog Junior KwikPen will be available now in U.S. Lilly KwikPen vs. Sanofi Solostar. Which insulin pen is going to win the race?
  15. Diabetes - Lilly's competition with Sanofi and Novo Nordisk

    Lilly's Humalog Junior KwikPen will be available now in U.S. Lilly KwikPen vs. Novo Nordisk FlexPen vs. Sanofi Solostar. Which insulin pen is going to win the race?
  16. sanofi director level

    Other than posting to new positions, is there a magic formula to get recognition to move to higher levels in the company? Strong performance doesn't seem to do the trick any more. Seems upper levels are stacked leaving little room for growth.
  17. Security Non-Operations?

    What's happening there? Half of them have been moved out. Last week someone was fired and another resigned (a good, senior manager with 15 years). Guess the new boss is making her mark ... and not in a good way.
  18. Lemtrada

    anyone's thoughts on this drug? will definitely be a niche drug aimed just for patients who basically have failed everything under the sun. curious about JC positive patients and immunosuppression with this therapy. heard being approved middle of november with a price tag around 100k, rigorous...